Close Menu


Mirna Therapeutics and collaborators at the University of Zurich reported last week that the company's therapeutic microRNA-34a mimic, dubbed MRX34, could inhibit tumor growth in an animal model of lymphoma, expanding the potential use of the agent to new cancer types.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Ventana is developing a companion diagnostic test for an oncology drug developed by Seattle Genetics and Millennium Pharmaceuticals under a deal announced today.

By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.

Through a genome-wide association study involving hundreds of individuals treated for Hodgkin's disease as children, researchers have identified a pair of variants near the PRDM1 gene that increase the risk of a radiation-related second cancer following this treatment.

The Leukemia and Lymphoma Society grant will fund genome-wide analysis research.

The study confirmed expected immune system behavior and offered insights into the transition of hematopoietic cells through known stages of development. It also provided a profile of normal signaling against which data on diseased cells such as cancer cells can be compared, said one of the researchers.

In the first study, four AIDS patients with lymphoma received treatment and are doing well, with no signs of treatment-related adverse effects.


The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.